Last reviewed · How we verify
Betablocker
At a glance
| Generic name | Betablocker |
|---|---|
| Sponsor | Oslo University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- MEdical Treatment in Idiopathic Ventricular Fibrillation Patients (PHASE4)
- Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease (PHASE2, PHASE3)
- STunning in Acute Myocardial Infarction - BAS (PHASE4)
- BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function (PHASE4)
- TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion" (PHASE4)
- Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation (NA)
- Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction (PHASE4)
- Beta-blockers to Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betablocker CI brief — competitive landscape report
- Betablocker updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI